peripheral arterial disease/tyrosine

הקישור נשמר בלוח

בחר סוג מיון

עמוד 1 מ 25 תוצאות

Peripheral Artery Disease and Stroke

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Peripheral artery disease (PAD) and stroke can occur as vascular complication of anticancer treatment. Although the mechanisms, monitoring, and management of cardiotoxicities have received broad attention, vascular toxicities remain often underrecognized. In addition, the development of new

Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

The second-generation tyrosine kinase inhibitor (TKI) of the BCR-ABL1 oncoprotein nilotinib used in patients with chronic myeloid leukemia is suspected to increase the risk of arterial occlusion, especially in patients with pre-existing cardiovascular risk factors or established cardiovascular

AgeR deletion decreases soluble fms-like tyrosine kinase 1 production and improves post-ischemic angiogenesis in uremic mice

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Peripheral arterial disease occurs more frequently and has a worse prognosis in patients with chronic kidney disease (CKD). The receptor for advanced glycation end products (RAGE) is involved in multiple aspects of uremia-associated vasculopathy. Previous data suggest that the RAGE pathway may

Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) has been associated with progressive peripheral arterial disease and, more recently, rare cases of intracranial vascular stenosis have been reported. We report the fourth case of TKI treatment associated intracranial

Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Metabolomic signature of arterial stiffness in male patients with peripheral arterial disease.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Arterial stiffness is an independent determinant of cardiovascular risk and a marker of subclinical organ damage. Metabolomics may facilitate identification of novel low-molecular cardiovascular risk factors. The aim of the present study was to compare metabolic signatures and functional-biochemical

Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Target therapy can cause various cardiovascular complications. The aim of this study was to evaluate the burden of cardiovascular complications related to treatment with anti-BCR-ABL tyrosine kinase inhibitors (TKIs) and to determine if there are differences between the latest- and

ADAM12: a genetic modifier of preclinical peripheral arterial disease.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

In prior studies from multiple groups, outcomes following experimental peripheral arterial disease (PAD) differed considerably across inbred mouse strains. Similarly, in humans with PAD, disease outcomes differ, even when there are similarities in risk factors, disease anatomy, arteriosclerotic

Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

The use of vascular endothelial growth factor inhibitors such as sorafenib is limited by a risk of severe cardiovascular toxicity. A 28-year-old man with acute myeloid leukemia treated with prednisone, tacrolimus, and sorafenib following stem cell transplantation presented with severe bilateral

[Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

The development of tyrosine kinase inhibitors (TKI) has revolutionized management of patients with chronic myeloid leukemia (CML), transforming this fatal disease into a chronic disease with nearly normal life expectancy. Nilotinib is a second generation TKI targeting the oncoprotein BCR-ABL used in

The role of C-reactive protein in innate and acquired inflammation: new perspectives.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

The participation of C-reactive protein (CRP) in host defense against microorganisms has been well described. More controversial has been its role in chronic conditions such as cardiovascular disease. Our recent publications explain the reasons for some of the confusion concerning CRP as a risk

Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND Critical limb ischemia (CLI) is a severe peripheral arterial disease, characterized by rest pain, ulcers and gangrene in the legs. Gas6 is a vitamin K-dependent protein, which binds and activates the tyrosine kinase receptor Axl. Gas6-mediated Axl-signaling influences endothelial

Enhanced peripheral dopamine impairs post-ischemic healing by suppressing angiotensin receptor type 1 expression in endothelial cells and inhibiting angiogenesis.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Increased circulating catecholamines have been linked with cardiovascular anomalies as well as with peripheral vascular diseases. Although the roles of epinephrine and norepinephrine have received considerable attention, the role of the other catecholamine, dopamine, has been less studied. Since

Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Previously authors have recently described an association between nilotinib therapy for chronic myeloid leukemia (CML) and severe peripheral artery disease, coronary artery disease and sudden death. We present a case report of a male patient with CML who received nilotinib therapy. He developed

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Tyrosine-kinase inhibitors (TKIs) can be associated with vascular events (VEs). The expected VE rates in patients with chronic myeloid leukemia (CML) are unknown. The present study examined the event rates and mortality among elderly patients with and without CML. Linked Surveillance, Epidemiology,

קודם
1
2
הַבָּא

הצטרפו לדף הפייסבוק שלנו

Herbal & Natural Medicine

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע

עובד ב 55 שפות
מרפא צמחי מרפא מגובה על ידי מדע
זיהוי עשבי תיבול על ידי דימוי
מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
קרא פרסומים מדעיים הקשורים לחיפוש שלך
חפש עשבי מרפא על פי השפעותיהם
ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים

הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם